Serous macular detachment associated with waldenstrom macroglobulinemia managed with ibrutinib: A case report and new insights into pathogenesis

Ilya Leskov, Alexander Knezevic, Manjot K. Gill*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Abstract

Purpose:To report a case of serous macular detachment in a patient with Waldenstrom macroglobulinemia treated with ibrutinib.Methods:The patient underwent a complete ophthalmic examination and imaging at presentation and at follow-up visits up to 13 months.Results:At presentation, there were serous macular detachments bilaterally with no dye leakage on fluorescein angiography or vasculature abnormalities on optical coherence tomography angiography. After treatment with ibrutinib, there was near resolution of the patient's retinopathy with an improvement in vision at 13 months' follow-up.Conclusion:Serous macular detachments in Waldenstrom macroglobulinemia-associated retinopathy may be due to the disruption of the retinal pigment epithelium pump mechanism by hyperglobulinemia. The favorable course of this patient, treated with the novel tyrosine kinase inhibitor ibrutinib, suggests this may be the preferred treatment for Waldenstrom macroglobulinemia patients with associated retinopathy.

Original languageEnglish (US)
Pages (from-to)490-494
Number of pages5
JournalRetinal Cases and Brief Reports
Volume15
Issue number4
DOIs
StatePublished - Jul 1 2021

Funding

This work was partly funded by an unrestricted grant from Research to Prevent Blindness.

Keywords

  • Waldenstrom macroglobulinemia
  • ibrutinib
  • optical coherence tomography angiography
  • retinopathy
  • serous macular detachment

ASJC Scopus subject areas

  • Ophthalmology

Fingerprint

Dive into the research topics of 'Serous macular detachment associated with waldenstrom macroglobulinemia managed with ibrutinib: A case report and new insights into pathogenesis'. Together they form a unique fingerprint.

Cite this